Vaxent
Memphis
About Vaxent
Vaxent’s lead product in development is a subunit vaccine against group A streptococcus which has been tested in early stage human clinical trials. The company plans to use its core competency in protein vaccine technology to advance its lead product in clinical testing, as well as develop other new vaccines against infectious diseases.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $152.5K
- Funding stage: Seed
- Last round: Debt Financing (Mar 2015)
Industries & Categories
Biotechnology
Canonical: https://fsome.com/organization/vaxent-2656561 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.